At Multiscreening, we developed a patented technology to introduce High Throughput Screening (HTS) for in vivostudies, allowing our customers to increase patent protected market sales by 4 months for each animal experimental series being performed.

Nanoporous MicroNeedle Arrays (npMNAs), integrated into a patch for drug delivery through the skin

MyMicroZoo™ is a company that offers microbiome analysis and web-based tools to gather meta-data (e.g. age, health-status, exercise logs, etc.) as service to the general public, allowing them to gain knowledge and understanding of their microbiota through an innovative platform.

Redefining neuromuscular drug development with advanced tissue models

MYRIAGON is developing a new class of medication to improve the quality of life for patients suffering from chemotherapy-induced neuropathic pain—a serious and often dose-limiting side effect of cancer treatment.

NatInLab develops promising compounds to battle Alzheimer's disease. We expect the compounds to be curative and show minimal side effects.

Stem cell technologies help bring better therapies to patients faster. Ncardia works with pharmaceutical and cell therapy companies worldwide to leverage the power of stem cell technologies in the development of novel therapies of multiple modalities.

NeoStartTrack is an innovative medical device that will give instant feedback on ventilation effectiveness and heart rate range. This enables direct and adequate adaptation of treatment.

Nephraxis develops a first-in-class therapy for sepsis-associated acute kidney injury, aiming to restore kidney function, prevent chronic damage, and reduce dialysis needs in this life-threatening condition.